Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
PCol I - Final Exam
Asthma drugs
| Question | Answer |
|---|---|
| early phase of asthma | bronchospasm |
| late phase of asthma | inflammation |
| B2 agonists (albuterol, salmeterol) MOA | relaxation of bronchiole smooth muscle |
| mast calls & T-lymphocytes release which mediators | histamine, tryptase, PGD2, LTC4, PAF, IL-4, IL-5, GM-CSF, TNF, TGF |
| eosinophils and neutrophils release which mediators | ECP, MBP, Protease, PAF |
| corticosteriods (beclomethasone, budesonide) MOA | broad anti-inflammatory actions |
| methylxanthines (theophylline) MOA | relaxation of bronchiole smooth muscle, effects on T-cells & eosinophils, increased mucociliary clearance (all via increase in cAMP) |
| cromolyn, nedocromil MOA | inhibit release of inflammatory mediators |
| leukotriene modifiers (zafirlukast, montelukast) MOA | antagonize the actions of LTs in the airways |
| muscarinic antagonists (ipratropium) MOA | muscarinic blockade in airways (blocks parasympathetic bronchoconstriction) |
| monoclonal antibodies (omalizumab) MOA | block IgE binding to mast cells |
| non-selective beta-agonists (3) used for asthma | epinephrine, ephedrine, isoproterenol |
| epinephrine - forms, onset & DA, adv rxns | injectable, aerosolinhalation: onset in 15 minduration: 60-90 minadv rxn: tachycardia, arrythmias, MI, skeletal muscle tremor |
| ephedrine for asthma (compared to epi) | oral adm; longer acting; more CNS effects; less potent |
| isoproterenol for asthma (compared to epi) | more potent; short onset of 5 min; 60-90 min duration |
| B2-selectives - onset, peak and DA if inhaled | onset at 1-5 min; peak at 30 min; lasts for 2-6 hrs |
| B2-selectives - oral DA | ~ 4-8 hrs |
| B2-selective drugs | albuterol (O/I), terbutaline (O/I), metaproterenol (O/I), bitolterol, pirbuterol, levalbuterol, salmeterol, formoterol |
| long-acting B2-selective drugs (12 hours or longer - useful for nocturnal symptoms) | salmeterol, formoterol --> both are dry powder inhalers |
| % of dose from MDI that actually makes it into the lung | 2 - 10% (90% deposited in the mouth) |
| tolerance to B2-selective agents tends to develop in response to which effect | tolerance to anti-inflammatory effects (mast cells and lymphocyets) more than tolerance to brochodilation |
| drug interaction with selective B2 agonists | interaction b/w non-selective beta-blockers and selective B2 agonist (counteract one aother) |
| Methylxanthine drugs (4) | theophylline, aminophylline, enprofylline (3-propylxanthine), and Roflumilast (newest agent in clinical trials) |
| two proposed methylxanthine MOA's (theophylline, aminophylline) | Increased cAMP results in:1) inhibtion of PDE4 (requires high conc.), 2) blockade of adenosine receptors, A1 in bronchiole sm (seen at therapeutic concentrations) |
| therapeutic index/range for methylxanthine drugs (theophylline, aminophylline) | 10-20 micrograms/ml (SEs appear around 20-25 micrograms/ml; higher than 40 can lead to seizures or arrhythmias) |
| metabolism of methylxanthines (theophylline, aminophylline) | CYP 450: 1A2 --> drug interactions |
| what's special about roflumilast | newest methylxanthine in clinical trials - high specificity for PDE4 in the lungs, less AE |
| what's special about enprofylline | potent bronchodilator that shows PDE4 inhibition, but no adenosine receptor antagonism |
| muscarinic antagonists for asthma (2) | Ipratropium & Tiotropium: Ipratropium bromide (quaternary ammonium compound)Tiotropium (Spiriva) – new agent with 24-hr duration of action |
| muscarinic antagonists (Ipratropium & Tiotropium) - MOA | blocking muscarinic receptors prevents parasympathetic bronchoconstriction - M3 receptor |
| which disease state should muscarinic antagonists be used carefully in | glaucoma |
| muscarinic antagonists (Ipratropium & Tiotropium) - time to peak, DA | Max effect in 30 min; duration of 3-5 hrs |
| Combivent (MDI) - 2 products | albuterol (b2 selective agonist) + ipratropium (muscarinic antagonist) |
| MOA for Cromolyn (Intal) & Nedocromil (Tilade) | inhibition of mast cell degranulation; inhibit mediator release from bronchial mast cells inhibition of parasympathetic & cough reflexes; not bronchodilators; no direct effects on smooth muscle |
| uses for for Cromolyn (Intal) & Nedocromil (Tilade) (mast cell degranulation inhibitors) | only prophylactic use – decrease immediate & late-phase asthmatic response to antigen-, exercise-, and irritant-induced asthma; effective when given before exercise or exposure to irritants |
Created by:
Krafty
Popular Science sets